The effect of angiotensin receptor blockade (ARB) on the regression of left ventricular hypertrophy in hemodialysis patients: Comparison between patients with D allele and non-D allele (ACE gene polymorphism)

Clinical Nephrology

Volumn 64, Issue 5, 2005, Pages 358-363

  Nakayama, M ^a   Nakano, H ^b,c   Tsuboi, N ^c   Kurosawa, T ^d   Tsuruta, Y ^e   Iwasaki, Y ^f   Yokoyama, K ^c   Hosoya, T ^c   Fukagawa, M ^g  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kashima Hospital   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Sumiyoshi Clinic Hopsital   (Japan)

^e Meiyo Clinic   (Japan)

^f OITA UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Japan)

^g KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ACE gene polymorphism; Angiotensin II receptor blockade (ARB); D allele; hypertrophy (LVH); Left ventricular

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; LOSARTAN;

ADULT; AGED; ALLELE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG DOSE REGIMEN; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; MALE; MEAN ARTERIAL PRESSURE;

EID: 27944460391     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp64358     Document Type: Article

References (22)

1. Berweck S, Hennig L, Sternberg C, Dingerkus H, Ludat K, Hampl H 2000 Cardiac mortality prevention in uremic patients. Therapeutic strategies with particular attention to complete correction of renal anemia. Clin Nephrol 53 (Suppl 1): S80-S85
2. Cannella G, Paoletti E, Barocci S, et al 1998 Angiotensin-converting enzyme gene polymorphism and reversibility of uremic left ventricular hypertrophy following long-term antihypertensive therapy. Kidney Int 54: 618-626
3. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S 1993 Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term anti-hypertensive therapy. Kidney Int 44: 881-886
4. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S 1997 Prolonged therapy with ACE inhibitors induced a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 30: 659-664
5. Harnett JD, Parfrey PS, Griffiths SM, Gault MH, Barre P, Guttmann RD 1988 Left ventricular hypertrophy in end-stage renal disease. Nephron 48: 107-115
6. Hernandez D, Lacalzada J, Salido E et al 2000 Regression of left ventricular hypertrophy by lisinopril after renal transplantation: Role of ACE gene polymorphism. Kidney Int 58: 889-897
7. Iwai N, Ohmichi N, Nakamura Y, Kinoshita M 1994 DD genotype of the angiotensin-converting-enzyme gene is a risk factor for left ventricular hypertrophy. Circulation 90: 2622-2628
8. Jeren-Struji'c B, Raos V, Jeren T, Horvatin-Godler S 2000 Morphologic and functional changes of left ventricle in dialyzed patients after treatment with recombinant human erythropoietin (r-HuEPO). Angiology 51: 131-139
9. Kanno Y, Kaneko K, Kaneko M, Kotaki S, Mimura T, Takane H, Syzuki H 2004 Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients. J Cardiovasc Pharmacol 43: 380-386
10. Klingbeil A U, Schneider M, Martus P, Messerli FH, Schmieder RE 2003 A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115: 41-46
11. Kuznetsova T, Staessen JA, Gasowski J, Nikitin Y, Ryabikov A, Fagard R 2000 Antihypertensive treatment modulates the association between the D/I ACE gene polymorphism and left ventricular hypertrophy: a meta-analysis. Journal of Human Hypertension 14: 447-454
12. Massimetti C, Pontillo, D, Feriozzi S, Costantini S, Capezzuto A, Ancarani E 1998 Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients. Blood Purif 16: 317-324
13. Ohishi M, Rakugi H, Ogihara T 1994 Association between a deletion polymorphism of the angiotensin-converting enzyme gene and left ventricular hypertrophy. N Engl J Med 331: 1097-1098
14. Prsad N et al 1994 The relationship between blood pressure and left ventricular mass in essential hypertension is observed only in the presence of the angiotensin-converting enzyme deletion allele. Q J Med 87: 659-662
15. Rigat B et al 1990 An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86: 1343-1346
16. Saracho R, Martin-Malo A, Martinez I, Aljama P, Montenegro J 1998 Evaluation of the losartan in hemodialysis (ELHE) study. Kidney Int 54 (Suppl 68): S125-S129
17. Schmieder RE, Martus P, Klingbill A 1996 Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 275: 1507
18. Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaki T 2002 Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 90: 256-261
19. Sica DA, Lo MW, Shaw WC, Keane WF, Gehr TWB, Halstenson CE, Lipschutz K, Furtek CI, Ritter MA, Shahinfar S 1995 The pharmacokinetics of losartan in renal insufficiency. J Hypertension 13 (Suppl 1): S49-S52
20. Sica DA, Halstenson CE, Gehr TWB, Keane WF 2000 Pharmacokinetics and blood pressure response of losartan in end-stage renal disease. Clin Pharmacokinet 38: 519-526
21. Yoshida H, Mitarai T, Kawamura T, et al 1995 Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin invest 96: 2162-2169
22. Zoccali C, Mallamaci F, Tripepi G, et al 1999 Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients. J Hypertens 17: 1751-1758